Cheetah Medical Set To Compete In Fast-Growing Hemodynamic Monitoring Market
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently, driven by rising cost pressures on hospitals, demographics, and new noninvasive alternatives to conventional hemodynamic monitoring technologies that require the insertion of an arterial line or pulmonary artery catheter.
You may also be interested in...
Edwards Lifesciences announced that it was acquiring private Dutch company BMEYE BV, the developer of a new noninvasive technology for hemodynamic monitoring. Noninvasive hemodynamic monitoring has long been “The Holy Grail” in critical care, and non-invasive technology opens up new applications and new markets for Edwards as well.
Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.
Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.